Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in
combination with apatinib plus NK cell in patients with advanced hepatocellular carcinoma.